Bulevirtide单药治疗48周在HDV相关代偿期肝硬化及临床显著门脉高压患者中的研究
该单中心研究纳入18例HDV相关代偿期肝硬化合并临床显著门脉高压且接受核苷(酸)类似物治疗的患者,给予Bulevirtide 2 mg/日单药治疗48周。结果显示HDV RNA下降3.1 log IU/ml、5例(23%)转阴,ALT复常率83%,联合应答率67%,安全性良好,无停药或失代偿事件。
要点
- HDV RNA中位下降3.1 log IU/ml,5例(23%)转阴,病毒学应答率78%。
- ALT中位降至35 U/L,83%患者复常,联合应答率67%。
- 无失代偿事件或肝细胞癌发生,胆汁酸升高均无症状。
核心结论
- 48周Bulevirtide 2 mg/日单药治疗对HDV相关代偿期肝硬化合并临床显著门脉高压的难治患者安全有效。
研究设计与样本
- 单中心研究,连续纳入18例HDV相关代偿期肝硬化合并临床显著门脉高压且接受核苷(酸)类似物治疗的患者,给予Bulevirtide 2 mg/日单药治疗48周。
- 在基线、第4周、第8周及之后每8周收集临床和病毒学特征,HDV RNA采用Robogene 2.0定量(检测下限6 IU/ml)。
主要发现
- 18例白种人患者中位(IQR)年龄48(29-77)岁,67%为男性;中位血小板计数70(37-227)×10³/μl,肝硬度值16.4(7.8-57.8)kPa,ALT 106(32-222)U/L,HBsAg 3.7(2.5-4.3)log IU/ml,HDV RNA 4.9(3.3-6.6)log IU/ml。
- 48周治疗期间HDV RNA下降3.1(0.2-4.3)log IU/ml(与基线相比p<0.001),5例(23%)转阴;14例(78%)出现病毒学应答,2例(11%)无应答。
- ALT降至35(15-86)U/L(与基线相比p<0.001),83%患者复常;67%患者出现联合应答;天冬氨酸氨基转移酶和γ-谷氨酰转移酶水平显著改善。
- 白蛋白值显著升高,胆红素保持稳定;病毒学应答患者肝硬度值显著改善,血小板计数无变化;无患者出现失代偿事件或肝细胞癌。
- Bulevirtide耐受良好,无患者停药,胆汁酸升高完全无症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Bulevirtide (BLV) has recently been conditionally approved for the treatment of chronic hepatitis delta (CHD) in Europe, but its effectiveness and safety in patients with compensated cirrhosis and clinically significant portal hypertension (CSPH) are unknown. METHODS: Consecutive patients with HDV-related compensated cirrhosis and CSPH who started BLV 2 mg/day were enrolled in this single-center study. Clinical/virological characteristics were collected at baseline, weeks 4, 8 and every 8 weeks thereafter. HDV RNA was quantified by Robogene 2.0 (lower limit of detection 6 IU/ml). RESULTS: Eighteen Caucasian patients with compensated cirrhosis and CSPH under nucleos(t)ide analogue treatment were enrolled: median (IQR) age was 48 (29-77) years, and 67% were male. Median (IQR) platelet count was 70 (37-227) x103/μl, liver stiffness measurement (LSM) 16.4 (7.8-57.8) kPa, alanine aminotransferase (ALT) 106 (32-222) U/L, HBsAg 3.7 (2.5-4.3) log IU/ml, HDV RNA 4.9 (3.3-6.6) log IU/ml. During 48 weeks of BLV monotherapy, HDV RNA declined by 3.1 (0.2-4.3) log IU/ml (p <0.001 vs. baseline), becoming undetectable in 5 patients (23%). A virological response was observed in 14 (78%) patients while a non-response was observed in 2 (11%). ALT decreased to 35 (15-86) U/L (p <0.001 vs. baseline), normalizing in 83% of patients. A combined response was observed in 67% of patients. Aspartate aminotransferase and gamma-glutamyltransferase levels significantly improved. Concerning liver function parameters, albumin values significantly increased and bilirubin remained stable. LSM significantly improved in patients with virological response, while platelet count was unchanged. None of the patients developed decompensating events or hepatocellular carcinoma. BLV was well tolerated, no patient discontinued treatment and the increase in bile acids was fully asymptomatic. CONCLUSIONS: A 48-week course of BLV 2 mg/day monotherapy is safe and effective even for difficult-to treat patients with HDV-related compensated cirrhosis and CSPH. LAY SUMMARY: Hepatitis delta virus (HDV) is associated with the most severe form of viral hepatitis. A new treatment for HDV called bulevirtide has recently received conditional approval for patients with chronic HDV infection. However, its safety and effectiveness in patients with more advanced liver disease is not known. Herein, we show that it is safe and effective in patients with HDV-related cirrhosis and clinically significant portal hypertension.
引用
- Degasperi E, Anolli MP, Uceda Renteria SC, et al. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. J Hepatol. 2022. PMID: 35973578. doi:10.1016/j.jhep.2022.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。